Browsing by Autor "Mario J. Grijalva"

Now showing 1 - 6 of 6

Development of Peptide-Based Lineage-Specific Serology for Chronic Chagas Disease: Geographical and Clinical Distribution of Epitope Recognition
(Public Library of Science, 2014) Tapan Bhattacharyya; Andrew K. Falconar; Alejandro O. Luquetti; Jaime A. Costales; Mario J. Grijalva; Michael D. Lewis; Louisa A. Messenger; Trang T. Tran; Juan David Ramírez; Felipe Guhl
These results demonstrate the considerable potential for synthetic peptide serology to investigate the infection history of individuals, geographical and clinical associations of T. cruzi lineages.
Dynamics of Sylvatic Chagas Disease Vectors in Coastal Ecuador Is Driven by Changes in Land Cover
(Public Library of Science, 2014) Mario J. Grijalva; D. Teran; Olivier Dangles
We propose a framework for identifying the factors affecting the yearly distribution of sylvatic T. cruzi vectors. Beyond providing key basic information for the control of human habitat colonization by sylvatic vector populations, our framework highlights the importance of both environmental and sociological factors in shaping the spatio-temporal population dynamics of triatomines. A better understanding of the dynamics of such socio-ecological systems is a crucial, yet poorly considered, issue for the long-term control of Chagas disease.
Multilocus analysis uncovers the evolution of the Rhodniini tribe, vectors of Trypanosoma cruzi
(Nature Portfolio, 2025) Carolina Hernández; Fabian C. Salgado‐Roa; Carolina Pardo‐Díaz; João Aristeu da Rosa; Jader de Oliveira; Cléber Galvão; Simone Patrícia Carneiro Freitas; José E. Calzada; Lineth García; Mario J. Grijalva
In this study, we investigate the origin and diversification of Trypanosoma cruzi vectors within the Rhodniini tribe (Triatominae subfamily) through phylogenetic analyses based on eight genes from 17 species and 497 specimens-the largest sampling of this tribe to date. Our results predominantly support the paraphyly of the genus Rhodnius, with the three Psammolestes species forming a well-supported monophyletic clade nested within it. In two reconstructions, however, Psammolestes and Rhodnius are recovered as reciprocally monophyletic, each with strong support. In Rhodnius, we find monophyletic pallescens and pictipes groups, but a paraphyletic prolixus group, with persistent phylogenetic discordances underscoring uncertainties in species placements. Divergence estimates suggest Rhodniini originated around 5.26 million years ago, notably more recent than previously thought. Evolution within the tribe appears shaped by geography, gene flow, and incomplete lineage sorting rather than traditional taxonomy. Only four species-P. arthuri, R. ecuadoriensis, R. neivai, and R. neglectus-are consistently supported across analyses, likely diversifying during Pleistocene climate changes. Other Rhodniini species may represent a panmictic population with minor structuring influenced by the Andes uplift. This study underscores the need for integrative research combining genetic, ecological, and biogeographical data to fully understand Rhodniini speciation and diversification.
Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus
(Public Library of Science, 2020) Julio Alonso-Padilla; Marcelo Abril; Belkisyolé Alarcón de Noya; Igor C. Almeida; Andrea Angheben; Tania Araujo Jorge; Eric Chatelain; Mónica I. Esteva; Joaquím Gascón; Mario J. Grijalva
ISGlobal work is supported by the Departament d’Universitats i Recerca de la Generalitat de Catalunya, Spain (AGAUR; 017SGR00924) and by the Instituto de Salud Carlos III (ISCIII) RICET Network for Cooperative Research in Tropical Diseases (ISCIII; RD16/0027/0004 - PI1290) and FEDER. MJP research is supported by the Ministry of Health, Government of Catalonia (PERIS 2016-2010 SLT008/18/00132). ICA, JG, and FT are supported by the grant number U01AI129783 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). ICA is also partly supported by the grant number 5U54MD007592 from the National Institute on Minority Health and Health Disparities (NIMHD), NIH. MCL and MCT were supported by ISCIII RICET grant RD16/0027/0005 - PI1290 and FEDER and by grants SAF2016-81003-R and SAF2016-80998-R from the Spanish “Programa Estatal I+D+i (MINECO)”. AA's work was supported by the Italian Ministry of Health “Fondi Ricerca Corrente - Linea 3, progetto 9” to IRCCS Sacro Cuore Don Calabria Hospital. JR was supported by CONACyT Fossis grant #261006. The Drugs for Neglected Diseases initiative (DNDi) is grateful to its donors, public and private, who have provided funding to DNDi since its inception in 2003. A full list of DNDi's donors can be found at http://www.dndi.org/donate/donors/. FIND is grateful to its donors, public and private, who have helped bring innovative new diagnostics for diseases of poverty. A full list of FIND’s donors can be found at: https://www.finddx.org/partners-donors/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Towards a Paradigm Shift in the Treatment of Chronic Chagas Disease
(American Society for Microbiology, 2013) Rodolfo Viotti; Belkisyolé Alarcón de Noya; Tânia Cremonini de Araújo-Jorge; Mario J. Grijalva; Felipe Guhl; Manuel Carlos López; Janine M. Ramsey; Isabela Ribeiro; Alejandro G. Schijman; Sergio Sosa‐Estáni
Treatment for Chagas disease with currently available medications is recommended universally only for acute cases (all ages) and for children up to 14 years old. The World Health Organization, however, also recommends specific antiparasite treatment for all chronic-phase Trypanosoma cruzi-infected individuals, even though in current medical practice this remains controversial, and most physicians only prescribe palliative treatment for adult Chagas patients with dilated cardiomyopathy. The present opinion, prepared by members of the NHEPACHA network (Nuevas Herramientas para el Diagnóstico y la Evaluación del Paciente con Enfermedad de Chagas/New Tools for the Diagnosis and Evaluation of Chagas Disease Patients), reviews the paradigm shift based on clinical and immunological evidence and argues in favor of antiparasitic treatment for all chronic patients. We review the tools needed to monitor therapeutic efficacy and the potential criteria for evaluation of treatment efficacy beyond parasitological cure. Etiological treatment should now be mandatory for all adult chronic Chagas disease patients.
Would tropical climatic variations impact the genetic variability of triatomines: Rhodnius ecuadoriensis, principal vector of Chagas disease in Ecuador?
(Elsevier BV, 2020) Anita G. Villacís; Juan José Bustillos; Stéphanie Depickère; Dino Sánchez; César A. Yumiseva; Ana Troya-Zuleta; Christian Barnabé; Mario J. Grijalva; Simone Frédérique Brénière